About 23andMe
23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.
Headquarters
23andMe, Sunnyvale
Founded
2006-04-01
Industry
Biotechnology, Genetics, Life Science
Last Funding Type
Post Ipo Equity
Valuation
11
Total Funding
$1.12 billion dollars
IPO Status
Public
Financial
23andMe is advancing in genetic analysis and ancestry determination. They are developing methods for analyzing genetic information between family members, finding relatives in databases, and determining identity-by-descent relatedness. Their research includes ancestry painting and ancestry composition determination, which involve displaying ancestral data and estimating parental contributions. They also focus on genetic-based recommendations and polygenic risk stratification for diseases like type 2 diabetes. These efforts highlight 23andMe's commitment to enhancing genetic insights and personalized health assessments.
Funding Rounds
14
Number of Lead Investors
7
Total Funding Amount
$1.12 billion dollars
Number of Investors
36